DNLI
Price
$13.92
Change
-$0.04 (-0.29%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
2.03B
Earnings call today
GLUE
Price
$4.22
Change
-$0.16 (-3.65%)
Updated
Aug 11, 03:00 PM (EDT)
Capitalization
269.41M
87 days until earnings call
Interact to see
Advertisement

DNLI vs GLUE

Header iconDNLI vs GLUE Comparison
Open Charts DNLI vs GLUEBanner chart's image
Denali Therapeutics
Price$13.92
Change-$0.04 (-0.29%)
Volume$12.6K
Capitalization2.03B
Monte Rosa Therapeutics
Price$4.22
Change-$0.16 (-3.65%)
Volume$100
Capitalization269.41M
DNLI vs GLUE Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. GLUE commentary
Aug 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and GLUE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 11, 2025
Stock price -- (DNLI: $13.96 vs. GLUE: $4.38)
Brand notoriety: DNLI and GLUE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 142% vs. GLUE: 93%
Market capitalization -- DNLI: $2.03B vs. GLUE: $269.41M
DNLI [@Biotechnology] is valued at $2.03B. GLUE’s [@Biotechnology] market capitalization is $269.41M. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileGLUE’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • GLUE’s FA Score: 0 green, 5 red.
According to our system of comparison, GLUE is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 3 TA indicator(s) are bullish while GLUE’s TA Score has 5 bullish TA indicator(s).

  • DNLI’s TA Score: 3 bullish, 6 bearish.
  • GLUE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, GLUE is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а +3.87% price change this week, while GLUE (@Biotechnology) price change was -8.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +22.22%. For the same industry, the average monthly price growth was +31.78%, and the average quarterly price growth was +19.63%.

Reported Earning Dates

DNLI is expected to report earnings on Aug 11, 2025.

GLUE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+22.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.03B) has a higher market cap than GLUE($269M). DNLI YTD gains are higher at: -31.501 vs. GLUE (-36.888). GLUE has higher annual earnings (EBITDA): 6.14M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. GLUE (326M). GLUE has less debt than DNLI: GLUE (41.9M) vs DNLI (48.6M). GLUE has higher revenues than DNLI: GLUE (159M) vs DNLI (0).
DNLIGLUEDNLI / GLUE
Capitalization2.03B269M754%
EBITDA-505.16M6.14M-8,223%
Gain YTD-31.501-36.88885%
P/E RatioN/A8.23-
Revenue0159M-
Total Cash818M326M251%
Total Debt48.6M41.9M116%
FUNDAMENTALS RATINGS
DNLI: Fundamental Ratings
DNLI
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
83
P/E GROWTH RATING
1..100
98
SEASONALITY SCORE
1..100
38

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DNLIGLUE
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
87%
Momentum
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 4 days ago
88%
MACD
ODDS (%)
Bullish Trend 4 days ago
86%
Bearish Trend 4 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 12 days ago
77%
Bullish Trend 25 days ago
88%
Declines
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
86%
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
82%
Bullish Trend 4 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SCGLF63.84N/A
N/A
Societe Generale
MNXBF5.38N/A
N/A
Monex Group, Inc.
NRXXY13.15N/A
N/A
NORDEX SE
CRTAF12.35N/A
N/A
Cartica Acquisition Corp.
BBOE0.65N/A
N/A
Black Box Entertainment Ltd.

GLUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLUE has been loosely correlated with EYPT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GLUE jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLUE
1D Price
Change %
GLUE100%
+3.55%
EYPT - GLUE
46%
Loosely correlated
N/A
IMNM - GLUE
43%
Loosely correlated
-1.82%
DNLI - GLUE
42%
Loosely correlated
-1.90%
ATXS - GLUE
42%
Loosely correlated
-6.15%
NRIX - GLUE
40%
Loosely correlated
-2.28%
More